Roll Over Study to Provide Idelalisib to Participants Previously Treated

Updated 06/21/2024

Status Terminated

Clinical Trial Summary

The primary objective of this study is to provide idelalisib to participants receiving GS-9820 in Gilead-sponsored Study GS-US-315-0102 at the time of study closure.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02739360
Study type	Interventional
Source	Gilead Sciences
Contact
Status	Terminated
Phase	Phase 4
Start date	May 4, 2016
Completion date	December 28, 2017

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01947140` - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies	Phase 1/Phase 2
	Completed	`NCT00383994` - Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation	Phase 1
	Terminated	`NCT01013818` - A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies	Phase 1
	Recruiting	`NCT04329728` - The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies	Phase 1/Phase 2
	Terminated	`NCT01998035` - Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies	Phase 1/Phase 2
	Completed	`NCT01705847` - A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies	Phase 1
	Completed	`NCT00406809` - A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies	Phase 1/Phase 2
	Terminated	`NCT00992732` - Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders	Phase 2
	Active, not recruiting	`NCT02452697` - Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT	Phase 2
	Not yet recruiting	`NCT06047886` - CD34 Selection Using the Automated CliniMACS Prodigy	Phase 1
	Completed	`NCT02181478` - Intra-Osseous Co-Transplant of UCB and hMSC	Early Phase 1
	Terminated	`NCT01596127` - Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System	Phase 1/Phase 2
	Completed	`NCT00820508` - Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies	Phase 1
	Recruiting	`NCT05371054` - Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies	Phase 1/Phase 2
	Completed	`NCT00529438` - RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies	Phase 1
	Completed	`NCT01435447` - Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies	Phase 2
	Completed	`NCT00508807` - RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies	Phase 1
	Completed	`NCT02091063` - ACY-1215 for Relapsed/Refractory Lymphoid Malignancies	Phase 1/Phase 2